Page last updated: 2024-10-25

cimetidine and Granulocytic Leukemia, Chronic

cimetidine has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Douer, D1
Ben-Bassat, I1
Kneller, A1
Chitayat, SD1
Shaked, N1
Salzberg, S1
Ramot, B1

Other Studies

1 other study available for cimetidine and Granulocytic Leukemia, Chronic

ArticleYear
Synergism of H2 histamine receptor antagonists with alpha-interferon to inhibit the growth of leukemic and normal hematopoietic progenitors.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Cell Division; Cimetidine; Depression, Chemical; Drug Screening Assays, Antitumor; Drug Synergism; H

1990